Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT00331214




Registration number
NCT00331214
Ethics application status
Date submitted
26/05/2006
Date registered
29/05/2006
Date last updated
17/04/2013

Titles & IDs
Public title
Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido
Scientific title
Study to Evaluate the Efficacy and Safety of Transdermal Testosterone in Women With Hypoactive Sexual Desire Disorder on Concurrent Estrogen Replacement Therapy and Undergone Hysterectomy/Bilateral Oophorectomy
Secondary ID [1] 0 0
2001134 and Yr 2-4 OL
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hypoactive Sexual Desire Disorder 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Testosterone Transdermal System
Treatment: Drugs - placebo patch

Sham Comparator: Placebo - placebo patch for 6 months

Experimental: Testosterone - Testosterone patch


Treatment: Drugs: Testosterone Transdermal System
testosterone patch (300 mcg/day), patch changed twice a week for six months

Treatment: Drugs: placebo patch
placebo patch replaced every 3-4 days for 6 months
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
To assess the efficacy of testosterone transdermal system (TS) as measured by the change from baseline in the frequency of total satisfying sexual activity captured by the Sexual Activity Log (SAL).
Timepoint [1] 0 0
6 months
Secondary outcome [1] 0 0
To assess the efficacy measured by the change from baseline in sexual desire; personal distress as measured by the Personal Distress Scale score; the other 6 domains of the profile of Female Sexual Function; and the other 8 SAL endpoints.
Timepoint [1] 0 0
6 months

Eligibility
Key inclusion criteria
Eligible women must:

1. Be 20-70 years old and in generally good health

2. Have undergone hysterectomy and removal of both ovaries at least 6 months prior to
screening

3. Be receiving a stable dose of estrogen replacement therapy for at least 3 months prior
to screening with the intention of maintaining that regimen.

4. Be, in her own judgment, in a stable monogamous sexual relationship that is perceived
to be secure and communicative, for at least one year prior to study entry.

5. Meet the criteria for having hypoactive sexual desire disorder.
Minimum age
20 Years
Maximum age
70 Years
Sex
Females
Can healthy volunteers participate?
No
Key exclusion criteria
Eligible women must not:

1. Have received androgen therapy at any time during the past 3 months (during the past 7
months if therapy was an investigational implantable product)

2. Be experiencing any chronic or acute life stress relating to any major life change

3. Be experiencing depression and/or receiving medication for such illness or disorder

4. Have current severe skin problems (such as severe or cystic acne) or allergy to
adhesives (like the ones in bandages)

5. Have had a major illness, active gall bladder disease, or gynecological or breast
surgery within the last 6 months

6. Have a history of breast, endometrial, or other gynecological cancer at any time
before study participation or other cancer within the last 5 years

7. Have diabetes, a history of cerebrovascular disease, thromboembolic disorders, heart
attack, or angina at any time before study participation or thrombophlebitis within
the last 5 years

8. Have abnormal laboratory test results upon initial screening for this study

9. Have previously participated in P&GP study 1999068 or 1999092

10. Have previously participated in a clinical trial within 30 days or received an
investigation medication within 30 days.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/06/2002
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/07/2006
Sample size
Target
Accrual to date
Final
533
Recruitment in Australia
Recruitment state(s)
QLD
Recruitment hospital [1] 0 0
Research Site - Nedlands
Recruitment postcode(s) [1] 0 0
- Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Colorado
Country [2] 0 0
Canada
State/province [2] 0 0
Ontario

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Warner Chilcott
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study is designed to evaluate efficacy and safety of a testosterone patch as treatment
for low libido in surgically menopausal women who are taking estrogen therapy.
Trial website
https://clinicaltrials.gov/ct2/show/NCT00331214
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Johna Lucas, MD
Address 0 0
Procter and Gamble
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT00331214